Riskpilot← Back to searchSign inGet full accessKEBOMED A/S
A/SActiveCVR 28490704Formervangen 5Wholesale of pharmaceutical and medical goods · NACE 4646Est. 200523 employees
Revenue 2025
DKK 47,6M
+12% vs 2024
EBITDA margin
27.2%
+12% vs 2024
Equity ratio
51.3%
Financial strength
Net profit 2025
DKK 9,8M
+6% vs 2024
| Revenue | DKK 47,6M | +12% |
| EBITDA | DKK 12,9M | +12% |
| Net profit | DKK 9,8M | +6% |
| Total assets | DKK 134,4M | +54% |
| Equity | DKK 68,9M | +17% |
| Employees | 23 | — |
Legal name
KEBOMED A/S
CVR number
28490704
Legal form
Aktieselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
16. februar 2005
Share capital
DKK 1.007.981
Employees
23 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-06-30
Financial year
January – December
Signatory rights
Selskabet tegnes af to bestyrelsesmedlemmer i forening eller af et bestyrelsesmedlem i forening med en direktør.
Company purpose
Selskabets formål er handel af enhver art samt hermed beslægtet virksomhed.
Address
Formervangen 5
Phone
+4536398080
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 49.295 | 52.130 | 54.183 | 38.944 | 37.726 | 40.944 | 41.213 | 37.753 | 38.994 | 41.485 | 39.270 | 41.324 | 42.647 | 47.572 |
| Staff expenses | -0 | -19.627 | -0 | -0 | -0 | -0 | -16.604 | -15.856 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | 19.357 | 17.980 | 20.224 | 13.098 | 12.328 | 13.921 | 11.662 | 10.986 | 11.775 | 16.757 | 11.598 | 12.144 | 11.523 | 12.944 |
| Depreciation & amort. | -0 | -0 | -778 | -0 | -197 | -183 | -0 | -49 | 201 | -0 | -0 | -2 | -0 | -0 |
| EBIT | 19.357 | 17.980 | 19.446 | 13.098 | 12.131 | 13.739 | 11.662 | 10.938 | 11.573 | 16.757 | 11.598 | 12.142 | 11.523 | 12.944 |
| Net financials | 189 | 352 | -1.152 | -444 | -583 | -5.045 | 3.185 | -341 | 23 | -184 | 79 | 157 | 357 | -316 |
| Profit before tax | 19.547 | 21.220 | 18.294 | 12.655 | 11.548 | 8.694 | 14.847 | 10.596 | 11.597 | 16.573 | 11.677 | 12.299 | 11.880 | 12.628 |
| Tax | 4.964 | 5.415 | 4.627 | 2.901 | 2.574 | 1.932 | 3.276 | 2.342 | 2.574 | 3.667 | 2.585 | 2.755 | 2.647 | 2.800 |
| Net profit | 14.582 | 15.805 | 13.667 | 9.753 | 8.974 | 6.761 | 11.571 | 8.254 | 9.022 | 12.907 | 9.093 | 9.544 | 9.234 | 9.828 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 40.457 | 43.597 | 62.588 | 61.229 | 68.474 | 114.218 | 59.307 | 47.598 | 38.682 | 43.223 | 53.362 | 62.975 | 87.133 | 134.439 |
| Equity | 19.250 | 21.055 | 14.722 | 6.861 | 10.035 | 16.797 | 12.633 | 9.316 | 18.338 | 31.244 | 40.337 | 49.881 | 59.114 | 68.942 |
| Long-term debt | 5.414 | 300 | 0 | 0 | 0 | 0 | 0 | 0 | 1.228 | 3.638 | 2.487 | 2.045 | 2.647 | 2.800 |
| Short-term debt | 15.701 | 22.189 | 47.866 | 54.368 | 58.438 | 97.422 | 46.675 | 38.282 | 19.116 | 8.341 | 10.537 | 11.049 | 25.372 | 62.697 |
| Total debt | 21.116 | 22.490 | 47.866 | 54.368 | 58.438 | 97.422 | 46.675 | 38.282 | 20.345 | 11.979 | 13.024 | 13.094 | 28.019 | 65.497 |
EBITDA margin
27.2%
This company
15.8%
Market median
+72% vs market
20122025
Equity ratio
51.3%
This company
38.2%
Market median
+34% vs market
20122025
Return on equity
14.3%
This company
18.4%
Market median
+22% vs market
20122025
Net profit margin
20.7%
This company
8.1%
Market median
+156% vs market
20122025
Asset turnover
0.35×
This company
1.12×
Market median
-69% vs market
20122025
Debt / equity
0.95×
This company
0.62×
Market median
+53% vs market
20122025
- Annual report 2025Filed via CVR / Virk · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via CVR / Virk · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via CVR / Virk · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via CVR / Virk · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via CVR / Virk · Period 2020-07-01 – 2021-06-30
- Annual report 2020Filed via CVR / Virk · Period 2019-07-01 – 2020-06-30
- Annual report 2019Filed via CVR / Virk · Period 2018-07-01 – 2019-06-30
- Annual report 2018Filed via CVR / Virk · Period 2017-07-01 – 2018-06-30
- Annual report 2017Filed via CVR / Virk · Period 2016-07-01 – 2017-06-30
- Annual report 2016Filed via CVR / Virk · Period 2015-07-01 – 2016-06-30
- Annual report 2015Filed via CVR / Virk · Period 2014-07-01 – 2015-06-30
- Annual report 2014Filed via CVR / Virk · Period 2013-07-01 – 2014-06-30
- Annual report 2013Filed via CVR / Virk · Period 2012-07-01 – 2013-06-30
- Annual report 2012Filed via CVR / Virk · Period 2011-07-01 – 2012-06-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
HS Management | Management | 2005 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2006 | — | — | |
| Board of Directors | 2006 | — | — | |
| Board of Directors | 2005 | — | — | |
| Board of Directors | 2005 | — | — | |
| Chairman | 2014 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100.0% | 100.0% | 2013 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of KEBOMED A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Henrik Schjødt | Management | 0 companies |
| Jesper Smidt-Nielsen | Chairman | 0 companies |
| Søren Dalmark Kornerup | Board of Directors | 0 companies |
| Erik Nexøe | Board of Directors | 0 companies |
| Anders Bogason | Board of Directors | 0 companies |
| Niels Søren Frederik Kornerup | Chairman | 0 companies |